Navigation Links
Deloitte Report: Pharmaceutical Companies' Patent Cliff Could Bolster Mergers and Acquisitions

NEW YORK, Oct. 27 /PRNewswire/ --


"Acquisitions versus Product Development: An Emerging Trend in Life Sciences"


Phil Pfrang, partner, Deloitte & Touche LLP


Available immediately



Recent pharmaceutical mergers and acquisitions indicate a trend of consolidation in the industry. Companies are looking for ways to bolster their research and development pipelines and reduce costs by rationalizing their combined sales and reducing other corporate overhead. The specter of possible healthcare reforms and the fact that drugs representing more than $74 billion in sales will lose patent protection by 2012 are also driving a new trend of later-stage mergers.

Deloitte's report, "Acquisitions versus Product Development: An Emerging Trend in Life Sciences," indicates an increasing preference for deals involving companies with compounds in the later stages of development.

"With so many rapidly changing dynamics -- the patent cliff, healthcare reform and still-dry capital markets -- the trends in life sciences industry consolidation are almost certain to continue with a growing emphasis on those deals with companies involved with late stage developed compounds," said Pfrang. "Healthy companies have good cause to pursue deals that promise faster revenue streams and profits. Likewise, cash-strapped companies -- particularly firms with rich research and development pipelines -- are likely to seek deals rather than face other alternatives."

Pfrang noted that acquirers or licensees have the opportunity to cut costs while leveraging their clinical development capabilities to accelerate the filing and launch of deals with a higher likelihood of demonstrating approvable drug efficacy profiles.

"However while late-stage deals may have lower overall risk, later-stage deals and associated higher deal valuations can pose greater financial risk," Pfrang added. "This is because executing and integrating later-stage deals often presents a unique set of challenges and missteps that can have a high cost, including delaying product launch, or worse, compromising the entire program."

To download a copy of the paper, please visit:

To speak with Deloitte about the paper and related issues, please contact John La Place at 212-492-4267, or and Peter Poulos at 212-885-0588, or

About Deloitte

As used in this document, "Deloitte" means Deloitte & Touche LLP and Deloitte Services LP, which are separate subsidiaries of Deloitte LLP. Please see for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

SOURCE Deloitte

SOURCE Deloitte
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Advanced Health Media Named to Deloittes 2009 Technology Fast 500(TM)
2. Accuray Ranked 155th Fastest Growing Company in North America on Deloittes 2009 Technology Fast 500(TM)
3. Deloitte and Nonprofit Roundtable Host Real-World Disaster Exercise as Next Step in Developing Preparedness Plan for Greater Washington Region
4. American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant
5. American Heart Association Journal Report: Surgical Residents Perform Heart Surgery as Effectively as Staff Surgeons
6. American Heart Association Journal Report: Reducing Kids Salt Intake May Lower Soft Drink Consumption, Reducing Obesity, High Blood Pressure and Later Health Risks
7. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
8. Cumberland Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 10, 2009
9. Intercept Pharmaceuticals Announces Positive Phase II Results for INT-747 as a Treatment for Primary Biliary Cirrhosis
10. Bellicum Pharmaceuticals Announces $4.5 Million in New Funding
11. BioMarin Acquires Huxley Pharmaceuticals, Inc.
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... 25, 2015 USP 800 applies to ... (e.g. pharmacists, pharmacy technicians, nurses, physicians, physician assistants, ... chapter also covers all entities which store, prepare, ... other healthcare institutions, patient treatment clinics, physicians, practice ... --> What is the purpose ...
(Date:11/25/2015)... Asia -based venture ... and the New Investors will make a direct equity ... private placement. The financing will help IOPtima to continue ... in the treatment of glaucoma, as well as to ... system with the U.S. Food and Drug Administration, commencing ...
Breaking Medicine Technology:
(Date:11/25/2015)... BROOK, Ill. (PRWEB) , ... November 25, 2015 ... ... larger and potentially more aggressive than those found on mammography, according to a ... MRI findings of additional cancers not seen on mammography may necessitate a change ...
(Date:11/25/2015)... ... 2015 , ... As part of a global movement to ... together who want to combine talents and resources to help create sustainable communities ... The non-profit launched its first major fundraiser on November 6, 2015 at Bent ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in ... on several models of traditional and far-infrared saunas. , For traditional saunas, ... the most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... has been recognized once again for its stellar workplace culture with the company’s ... , Medical Solutions’ Cincinnati office was named a finalist in Cincinnati ...
Breaking Medicine News(10 mins):